What amount sold does Windham Life Sciences Partners IV, L.P. report in Form D filings?

The latest linked filings report $30.8M sold across 1 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Windham Life Sciences Partners IV, L.P.'s most recent SEC filing?

Windham Life Sciences Partners IV, L.P.'s most recent Form D filing was on 2025-11-13.

How many investors does Windham Life Sciences Partners IV, L.P. have?

The most recent Form D filing lists 51 investor(s).

What type of securities does Windham Life Sciences Partners IV, L.P. offer?

Windham Life Sciences Partners IV, L.P.'s SEC Form D filings indicate equity offerings.

Windham Life Sciences Partners IV, L.P.

CIK: 0001999637·Pooled Investment Fund·NEW YORK, NY·Limited Partnership·Founded 2023

Reported Sold

$30,784,955

Total Filings

Identified Offerings

Last Filed

Nov 13, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Pooled Investment Fund industry

SEC EDGAR

Offering filing timeline

Nov 13, 2025Form D/A — Amendment

Reported sold: $30,784,955 · Target: $150,000,000

Rule 506(b)·51 investors·Section 3(c), Section 3(c)(1)

Changed: Reported amount sold, Reported investors

Nov 15, 2024Form D/A — Amendment

Reported sold: $19,525,000 · Target: $150,000,000

Rule 506(b)·32 investors·Section 3(c), Section 3(c)(1)

Changed: Reported amount sold, Offering target, Reported investors

Nov 8, 2023Form D/A — Amendment

Reported sold: $1,250,000 · Target: $200,000,000

Rule 506(b)·3 investors·Section 3(c), Section 3(c)(1)

Changed: Exemptions

Nov 3, 2023Form D — New notice

Reported sold: $1,250,000 · Target: $200,000,000

Section 3(c)·3 investors·Section 3(c)(1)

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

75%

Latest reported sold across 1 identified offering

$30,784,955

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Adam E Fine

Related Person

Appears on 4 filings

Windham Life Sciences Partners General Partner IV, LLC

Related Person

Appears on 2 filings

Adam E Windham Life Sciences Partners General Partner IV, LLC

Related Person

Appears on 2 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Nov 13, 2025	Amendment	$150,000,000	$30,784,955	51
Nov 15, 2024	Amendment	$150,000,000	$19,525,000	32
Nov 8, 2023	Amendment	$200,000,000	$1,250,000	3
Nov 3, 2023	New	$200,000,000	$1,250,000	3

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

RLP II Vision LP

Pooled Investment Fund

Offering target: $137,402,000

Filed Oct 30, 2026